苯扎贝特联合醋酸甲羟孕酮治疗急性髓系白血病疗效观察分析

The curative effects and related analysis of bezafibrate combined medroxyprogesterone acetate in the treatment of AML

目的观察苯扎贝特联合醋酸甲羟孕酮治疗急性髓系白血病(AML)的疗效。方法收集AML患者40例,将其分为试验组(苯扎贝特联合醋酸甲羟孕酮治疗)6例、对照组(化疗)28例、放弃治疗组(未接受任何治疗)6例,通过前瞻性分析探讨苯扎贝特联合醋酸甲羟孕酮治疗AML的疗效及相关性分析。结果中位生存时间试验组为15周,对照组为24周,放弃治疗组为8周。结论苯扎贝特联合醋酸甲羟孕酮的治疗或能延长AML患者的生存时间,无明显不良反应。

Objective To observe the curative effects of bezafibrate combined medroxyprogesterone acetate in the treatment of AML .Methods 40 cases of AML patients were collected and devided into experimental group （bezafibrate combined medroxypro-gesterone acetate ,6 cases） ,control group （chemotherapy ,28 cases） and non-treatment group （6 cases） ,then through a prospective analysis we studied the curative effects and related results of bezafibrate combined medroxyprogesterone acetate in the treatment of AML .Results The median survival time of the experiment group （accepted bezafibrate combined medroxyprogesterone acetate ） was 15 weeks ;the median survival time of the control group （accepted chemotherapy ） was 24 weeks ;the median survival time of the giving up group（accepted any therapy ） was 8 weeks .Conclusion Bezafibrate combined medroxyprogesterone acetate could prolong the survival time of AML patients and there were no obvious adverse reactions .